The Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen

Send us Fan MailWhat if I told you there is a major genetic risk factor for heart attacks and strokes that affects roughly one in five people worldwide - but most people have never heard of it, and it isn't measured on a standard cholesterol test? Today we're exploring Lp(a), the hidden cardiovascular risk factor that could reshape the future of heart disease prevention.Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P., is Senior Vice President and Chief Medical Officer of Amgen ( https://www.amgen.com/about/leadership/senior-management/paul-burton ).Dr. Burton has built one of the most remarkable careers in modern medicine and biotechnology. After training as a physician and cardiovascular surgeon in the United Kingdom and earning a Ph.D. in molecular and cellular biology from Imperial College London, he transitioned into the biotechnology industry, where he has spent more than two decades leading the development of innovative medicines across cardiovascular disease, oncology, infectious disease, metabolic disorders and RNA therapeutics.Before returning to Amgen as Chief Medical Officer in 2023, Dr. Burton served as Chief Medical Officer of Moderna during one of the most consequential periods in modern public health, overseeing global medical strategy and pharmacovigilance. Prior to that he spent sixteen years at Johnson & Johnson, ultimately serving as Chief Global Medical Affairs Officer while helping pioneer digital medicine initiatives, including collaborations exploring virtual clinical trials.Today, Dr. Burton leads Amgen's worldwide medical organization, helping guide one of the industry's broadest research pipelines while translating breakthrough science into therapies that can improve - and potentially save - millions of lives.One of those efforts is Amgen's ambitious work targeting lipoprotein(a), or Lp(a), a genetically inherited cardiovascular risk factor affecting roughly one in five people worldwide. Through its investigational siRNA therapy olpasiran and the expansive OCEAN(a) clinical program, Amgen hopes to answer one of the biggest remaining questions in preventive cardiology: can dramatically lowering Lp(a) prevent heart attacks and strokes?Today we'll explore Dr. Burton's fascinating career, what it means to lead medical strategy at one of biotechnology's largest innovators, and why the next decade may fundamentally reshape how we prevent cardiovascular disease.#Cardiology #HeartDisease #LpA #LipoproteinA #PrecisionMedicine #RNAmedicine #GeneSilencing #Biotechnology #Biotech #Amgen #DrugDiscovery #PharmaceuticalInnovation #FutureOfMedicine #CardiovascularHealth #HeartHealth #MedicalInnovation #HealthcareInnovation #PreventiveMedicine #Genomics #SiRNA #LongevityScience #RegenerativeMedicine #ClinicalTrials #Pharma #LifeSciences #ProgressPotentialPossibilitiesSupport the show